amifostine anhydrous has been researched along with Diarrhea in 8 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 7.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| "Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis." | 5.10 | A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. ( Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D, 2002) |
| "High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs." | 3.88 | Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. ( Bashir, Q; Caimi, P; Champlin, R; Cooper, B; Covut, F; Creger, R; de Lima, M; Delgado, R; Gupta, V; Lazarus, HM; Malek, E; Qazilbash, M; Rondon, G; Vatsayan, A, 2018) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 3.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| "Hypotension was the most important adverse event of AMI infusion." | 2.70 | A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. ( Jantunen, E; Kuittinen, T; Nousiainen, T, 2002) |
| "Grade 2 proctitis was noted in 18." | 1.38 | Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. ( Abatzoglou, I; Koukourakis, MI; Panteliadou, M; Papadopoulou, A; Sismanidou, K; Touloupidis, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, E | 1 |
| Gupta, V | 1 |
| Creger, R | 1 |
| Caimi, P | 1 |
| Vatsayan, A | 1 |
| Covut, F | 1 |
| Bashir, Q | 1 |
| Champlin, R | 1 |
| Delgado, R | 1 |
| Rondon, G | 1 |
| Cooper, B | 1 |
| de Lima, M | 1 |
| Lazarus, HM | 1 |
| Qazilbash, M | 1 |
| Koukourakis, MI | 1 |
| Papadopoulou, A | 1 |
| Abatzoglou, I | 1 |
| Panteliadou, M | 1 |
| Sismanidou, K | 1 |
| Touloupidis, S | 1 |
| Garcia-Manero, G | 1 |
| Faderl, S | 1 |
| Giles, F | 1 |
| Thomas, D | 1 |
| Cortes, J | 1 |
| O'Brien, S | 1 |
| Davis, J | 1 |
| Kantarjian, HM | 1 |
| Estey, E | 1 |
| Jantunen, E | 1 |
| Kuittinen, T | 1 |
| Nousiainen, T | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Vadiaka, M | 1 |
| Zonios, D | 1 |
| Papalambros, E | 1 |
| Papantoniou, N | 1 |
| Margaris, H | 1 |
| Zografos, G | 1 |
| Rokana, S | 1 |
| Retalis, G | 1 |
| Koufos, C | 1 |
| Takahashi, I | 1 |
| Mitsuhashi, N | 1 |
| Itoh, J | 1 |
| Okazaki, A | 1 |
| Ikeda, H | 1 |
| Suto, H | 1 |
| Yamakawa, M | 1 |
| Nozaki, M | 1 |
| Miyaishi, K | 1 |
| Niibe, H | 1 |
| Capelli, D | 1 |
| Santini, G | 1 |
| De Souza, C | 1 |
| Poloni, A | 1 |
| Marino, G | 1 |
| Montanari, M | 1 |
| Lucesole, M | 1 |
| Brunori, M | 1 |
| Massidda, D | 1 |
| Offidani, M | 1 |
| Leoni, P | 1 |
| Olivieri, A | 1 |
| Delioukina, ML | 1 |
| Prager, D | 1 |
| Parson, M | 1 |
| Hecht, JR | 1 |
| Rosen, P | 1 |
| Rosen, LS | 1 |
4 trials available for amifostine anhydrous and Diarrhea
| Article | Year |
|---|---|
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy P | 2002 |
A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Feasibility Studies; Fe | 2002 |
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
Topics: Adolescent; Adult; Aged; Amifostine; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Blood Ce | 2000 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Pro | 2002 |
4 other studies available for amifostine anhydrous and Diarrhea
| Article | Year |
|---|---|
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Topics: Adult; Aged; Amifostine; Case-Control Studies; Combined Modality Therapy; Diarrhea; Disease-Free Sur | 2018 |
Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Topics: Aged; Amifostine; Carcinoma; Cytoprotection; Diarrhea; Dysuria; Humans; Male; Middle Aged; Proctitis | 2012 |
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Amifostine; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea | 2003 |
[Clinical use of radioprotector amifostine (YM-08310)].
Topics: Adolescent; Adult; Aged; Amifostine; Child; Diarrhea; Female; Head and Neck Neoplasms; Humans; Lymph | 1984 |